The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

In a statement today, the company said it supports recent precautionary measures and that thorough investigations are needed ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Chikungunya is a mosquito-borne tropical disease that causes intense joint pain and fever. Although it is rare in the U.S., about 100 to 200 cases are reported annually, mostly among Americans ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.